Frias Miguel A, Lecour Sandrine, James Richard W, Pedretti Sarah
Department of Internal Medicine; Clinical Diabetes Unit; Medical Faculty; University of Geneva; Geneva, Switzerland.
JAKSTAT. 2012 Apr 1;1(2):92-100. doi: 10.4161/jkst.19754.
High density lipoprotein (HDL) cholesterol has beneficial effects beyond its atheroprotective function in reverse cholesterol transport, including cardioprotection against ischemia reperfusion (IR) injuries. Two major constituents of HDL, namely the structural protein apolipoprotein AI (apoAI) and the sphingolipid sphingosine-1-phosphate (S1P) appear to contribute to this cardioprotective effect via the activation of intrinsic prosurvival signaling pathways that still remain to be clarified. Recently, a powerful prosurvival signaling pathway, termed the survivor activating factor enhancement (SAFE) pathway, which involves the activation of signal transducer and activator of transcription 3 (STAT3) and tumor necrosis factor α (TNF), has been shown to protect against ischemia-reperfusion injuries. The present review summarizes the evidence for the roles of HDL and S1P in cardioprotection and discusses the signaling pathways that have been implicated. It thus provides support for our contention that S1P should be considered in potential formulations of reconstituted HDL (reHDL) that may be tested for cardioprotection against coronary artery disease via the activation of the SAFE pathway.
高密度脂蛋白(HDL)胆固醇除了在逆向胆固醇转运中具有抗动脉粥样硬化保护功能外,还具有有益作用,包括对缺血再灌注(IR)损伤的心脏保护作用。HDL的两个主要成分,即结构蛋白载脂蛋白AI(apoAI)和鞘脂鞘氨醇-1-磷酸(S1P),似乎通过激活仍有待阐明的内在促生存信号通路来促成这种心脏保护作用。 最近,一种强大的促生存信号通路,即幸存者激活因子增强(SAFE)通路,已被证明可预防缺血再灌注损伤,该通路涉及信号转导和转录激活因子3(STAT3)和肿瘤坏死因子α(TNF)的激活。本综述总结了HDL和S1P在心脏保护中作用的证据,并讨论了相关的信号通路。因此,它支持了我们的观点,即在可能通过激活SAFE通路来测试对冠状动脉疾病心脏保护作用的重组HDL(reHDL)潜在配方中应考虑S1P。